nodes	percent_of_prediction	percent_of_DWPC	metapath
Imatinib—CYP1A2—chronic obstructive pulmonary disease	0.216	0.634	CbGaD
Imatinib—ALB—chronic obstructive pulmonary disease	0.125	0.366	CbGaD
Imatinib—PTGS1—Montelukast—chronic obstructive pulmonary disease	0.0391	0.122	CbGbCtD
Imatinib—CYP2C19—Formoterol—chronic obstructive pulmonary disease	0.025	0.0777	CbGbCtD
Imatinib—CYP2C19—Arformoterol—chronic obstructive pulmonary disease	0.025	0.0777	CbGbCtD
Imatinib—ABCA3—alveolus of lung—chronic obstructive pulmonary disease	0.0245	0.313	CbGeAlD
Imatinib—CYP2C9—Formoterol—chronic obstructive pulmonary disease	0.0208	0.0646	CbGbCtD
Imatinib—CYP2C9—Arformoterol—chronic obstructive pulmonary disease	0.0208	0.0646	CbGbCtD
Imatinib—CYP1A2—Aminophylline—chronic obstructive pulmonary disease	0.0196	0.061	CbGbCtD
Imatinib—CYP2D6—Arformoterol—chronic obstructive pulmonary disease	0.019	0.0591	CbGbCtD
Imatinib—CYP2D6—Formoterol—chronic obstructive pulmonary disease	0.019	0.0591	CbGbCtD
Imatinib—CYP2D6—Tiotropium—chronic obstructive pulmonary disease	0.0169	0.0526	CbGbCtD
Imatinib—ALB—Prednisone—chronic obstructive pulmonary disease	0.0162	0.0503	CbGbCtD
Imatinib—CYP3A4—Salbutamol—chronic obstructive pulmonary disease	0.0159	0.0496	CbGbCtD
Imatinib—CYP2C9—Montelukast—chronic obstructive pulmonary disease	0.0157	0.049	CbGbCtD
Imatinib—CYP3A4—Tiotropium—chronic obstructive pulmonary disease	0.0108	0.0335	CbGbCtD
Imatinib—CYP2C19—Prednisone—chronic obstructive pulmonary disease	0.0105	0.0326	CbGbCtD
Imatinib—CYP3A4—Aminophylline—chronic obstructive pulmonary disease	0.0103	0.0319	CbGbCtD
Imatinib—CYP3A4—Montelukast—chronic obstructive pulmonary disease	0.00916	0.0285	CbGbCtD
Imatinib—ABCB1—Prednisolone—chronic obstructive pulmonary disease	0.00897	0.0279	CbGbCtD
Imatinib—ABCB1—Prednisone—chronic obstructive pulmonary disease	0.00847	0.0263	CbGbCtD
Imatinib—CYP3A4—Prednisolone—chronic obstructive pulmonary disease	0.00537	0.0167	CbGbCtD
Imatinib—CYP3A4—Prednisone—chronic obstructive pulmonary disease	0.00507	0.0158	CbGbCtD
Imatinib—ABCA3—respiratory system—chronic obstructive pulmonary disease	0.00247	0.0316	CbGeAlD
Imatinib—DDR1—bronchus—chronic obstructive pulmonary disease	0.00188	0.024	CbGeAlD
Imatinib—DDR1—smooth muscle tissue—chronic obstructive pulmonary disease	0.00184	0.0235	CbGeAlD
Imatinib—DDR1—trachea—chronic obstructive pulmonary disease	0.00169	0.0215	CbGeAlD
Imatinib—CA3—respiratory system—chronic obstructive pulmonary disease	0.00134	0.0172	CbGeAlD
Imatinib—ABCA3—lung—chronic obstructive pulmonary disease	0.00131	0.0168	CbGeAlD
Imatinib—DDR1—lung—chronic obstructive pulmonary disease	0.00121	0.0155	CbGeAlD
Imatinib—CA3—connective tissue—chronic obstructive pulmonary disease	0.00118	0.0151	CbGeAlD
Imatinib—PIP4K2C—bronchus—chronic obstructive pulmonary disease	0.00116	0.0148	CbGeAlD
Imatinib—CA7—trachea—chronic obstructive pulmonary disease	0.00108	0.0138	CbGeAlD
Imatinib—PIP4K2C—trachea—chronic obstructive pulmonary disease	0.00104	0.0133	CbGeAlD
Imatinib—PDGFRA—respiratory system—chronic obstructive pulmonary disease	0.00103	0.0132	CbGeAlD
Imatinib—LCK—bronchus—chronic obstructive pulmonary disease	0.00103	0.0131	CbGeAlD
Imatinib—CA12—respiratory system—chronic obstructive pulmonary disease	0.000952	0.0122	CbGeAlD
Imatinib—LCK—trachea—chronic obstructive pulmonary disease	0.000923	0.0118	CbGeAlD
Imatinib—CSF1R—respiratory system—chronic obstructive pulmonary disease	0.000908	0.0116	CbGeAlD
Imatinib—PDGFRA—connective tissue—chronic obstructive pulmonary disease	0.000908	0.0116	CbGeAlD
Imatinib—Meclizine—CYP1A2—chronic obstructive pulmonary disease	0.00088	1	CrCbGaD
Imatinib—NQO2—bronchus—chronic obstructive pulmonary disease	0.000851	0.0109	CbGeAlD
Imatinib—CA12—connective tissue—chronic obstructive pulmonary disease	0.000838	0.0107	CbGeAlD
Imatinib—PDGFRA—smooth muscle tissue—chronic obstructive pulmonary disease	0.00083	0.0106	CbGeAlD
Imatinib—KIT—respiratory system—chronic obstructive pulmonary disease	0.000824	0.0105	CbGeAlD
Imatinib—PDGFRB—respiratory system—chronic obstructive pulmonary disease	0.000805	0.0103	CbGeAlD
Imatinib—CSF1R—connective tissue—chronic obstructive pulmonary disease	0.000799	0.0102	CbGeAlD
Imatinib—ABL2—lung—chronic obstructive pulmonary disease	0.00079	0.0101	CbGeAlD
Imatinib—NQO2—trachea—chronic obstructive pulmonary disease	0.000764	0.00976	CbGeAlD
Imatinib—PDGFRA—trachea—chronic obstructive pulmonary disease	0.000762	0.00974	CbGeAlD
Imatinib—CA1—respiratory system—chronic obstructive pulmonary disease	0.000754	0.00963	CbGeAlD
Imatinib—PIP4K2C—lung—chronic obstructive pulmonary disease	0.000747	0.00955	CbGeAlD
Imatinib—CSF1R—bronchus—chronic obstructive pulmonary disease	0.000747	0.00955	CbGeAlD
Imatinib—CSF1R—smooth muscle tissue—chronic obstructive pulmonary disease	0.000731	0.00934	CbGeAlD
Imatinib—KIT—connective tissue—chronic obstructive pulmonary disease	0.000726	0.00927	CbGeAlD
Imatinib—ABL1—respiratory system—chronic obstructive pulmonary disease	0.000718	0.00917	CbGeAlD
Imatinib—CA3—lung—chronic obstructive pulmonary disease	0.000714	0.00912	CbGeAlD
Imatinib—PDGFRB—connective tissue—chronic obstructive pulmonary disease	0.000709	0.00906	CbGeAlD
Imatinib—CA12—trachea—chronic obstructive pulmonary disease	0.000703	0.00899	CbGeAlD
Imatinib—KIT—bronchus—chronic obstructive pulmonary disease	0.000678	0.00867	CbGeAlD
Imatinib—CSF1R—trachea—chronic obstructive pulmonary disease	0.000671	0.00857	CbGeAlD
Imatinib—KIT—smooth muscle tissue—chronic obstructive pulmonary disease	0.000664	0.00848	CbGeAlD
Imatinib—LCK—lung—chronic obstructive pulmonary disease	0.000663	0.00848	CbGeAlD
Imatinib—PDGFRB—bronchus—chronic obstructive pulmonary disease	0.000663	0.00847	CbGeAlD
Imatinib—PDGFRB—smooth muscle tissue—chronic obstructive pulmonary disease	0.000648	0.00828	CbGeAlD
Imatinib—ABL1—connective tissue—chronic obstructive pulmonary disease	0.000632	0.00807	CbGeAlD
Imatinib—KIT—trachea—chronic obstructive pulmonary disease	0.000609	0.00778	CbGeAlD
Imatinib—PDGFRB—trachea—chronic obstructive pulmonary disease	0.000595	0.0076	CbGeAlD
Imatinib—ABL1—bronchus—chronic obstructive pulmonary disease	0.000591	0.00755	CbGeAlD
Imatinib—ABL1—smooth muscle tissue—chronic obstructive pulmonary disease	0.000578	0.00738	CbGeAlD
Imatinib—NQO2—lung—chronic obstructive pulmonary disease	0.000549	0.00701	CbGeAlD
Imatinib—PDGFRA—lung—chronic obstructive pulmonary disease	0.000547	0.007	CbGeAlD
Imatinib—ABL1—trachea—chronic obstructive pulmonary disease	0.00053	0.00678	CbGeAlD
Imatinib—CA12—lung—chronic obstructive pulmonary disease	0.000505	0.00646	CbGeAlD
Imatinib—CA2—respiratory system—chronic obstructive pulmonary disease	0.000489	0.00624	CbGeAlD
Imatinib—CSF1R—lung—chronic obstructive pulmonary disease	0.000482	0.00616	CbGeAlD
Imatinib—SLC47A1—lung—chronic obstructive pulmonary disease	0.00044	0.00563	CbGeAlD
Imatinib—KIT—lung—chronic obstructive pulmonary disease	0.000438	0.00559	CbGeAlD
Imatinib—CYP1A2—respiratory system—chronic obstructive pulmonary disease	0.000436	0.00557	CbGeAlD
Imatinib—CA2—connective tissue—chronic obstructive pulmonary disease	0.00043	0.0055	CbGeAlD
Imatinib—PDGFRB—lung—chronic obstructive pulmonary disease	0.000427	0.00546	CbGeAlD
Imatinib—CYP3A5—respiratory system—chronic obstructive pulmonary disease	0.00042	0.00537	CbGeAlD
Imatinib—CA2—bronchus—chronic obstructive pulmonary disease	0.000402	0.00514	CbGeAlD
Imatinib—ORM1—lung—chronic obstructive pulmonary disease	0.000401	0.00512	CbGeAlD
Imatinib—CA1—lung—chronic obstructive pulmonary disease	0.0004	0.00512	CbGeAlD
Imatinib—CA2—smooth muscle tissue—chronic obstructive pulmonary disease	0.000393	0.00503	CbGeAlD
Imatinib—ABL1—lung—chronic obstructive pulmonary disease	0.000381	0.00487	CbGeAlD
Imatinib—PTGS1—respiratory system—chronic obstructive pulmonary disease	0.000377	0.00482	CbGeAlD
Imatinib—CA2—trachea—chronic obstructive pulmonary disease	0.000361	0.00461	CbGeAlD
Imatinib—PTGS1—connective tissue—chronic obstructive pulmonary disease	0.000332	0.00425	CbGeAlD
Imatinib—PTGS1—smooth muscle tissue—chronic obstructive pulmonary disease	0.000304	0.00388	CbGeAlD
Imatinib—PTGS1—trachea—chronic obstructive pulmonary disease	0.000279	0.00356	CbGeAlD
Imatinib—CA2—lung—chronic obstructive pulmonary disease	0.000259	0.00332	CbGeAlD
Imatinib—ABCG2—lung—chronic obstructive pulmonary disease	0.00024	0.00307	CbGeAlD
Imatinib—CYP1A2—lung—chronic obstructive pulmonary disease	0.000231	0.00296	CbGeAlD
Imatinib—ABCB1—respiratory system—chronic obstructive pulmonary disease	0.000223	0.00285	CbGeAlD
Imatinib—CYP3A5—lung—chronic obstructive pulmonary disease	0.000223	0.00285	CbGeAlD
Imatinib—PTGS1—lung—chronic obstructive pulmonary disease	0.0002	0.00256	CbGeAlD
Imatinib—ABCB1—trachea—chronic obstructive pulmonary disease	0.000165	0.00211	CbGeAlD
Imatinib—Dry mouth—Salbutamol—chronic obstructive pulmonary disease	0.000144	0.000871	CcSEcCtD
Imatinib—Nervous system disorder—Montelukast—chronic obstructive pulmonary disease	0.000144	0.000868	CcSEcCtD
Imatinib—Thrombocytopenia—Montelukast—chronic obstructive pulmonary disease	0.000144	0.000867	CcSEcCtD
Imatinib—Abdominal distension—Prednisolone—chronic obstructive pulmonary disease	0.000144	0.000867	CcSEcCtD
Imatinib—Sepsis—Prednisone—chronic obstructive pulmonary disease	0.000143	0.000865	CcSEcCtD
Imatinib—Skin disorder—Montelukast—chronic obstructive pulmonary disease	0.000143	0.00086	CcSEcCtD
Imatinib—Oedema—Salbutamol—chronic obstructive pulmonary disease	0.000141	0.000853	CcSEcCtD
Imatinib—Anaphylactic shock—Salbutamol—chronic obstructive pulmonary disease	0.000141	0.000853	CcSEcCtD
Imatinib—Infection—Salbutamol—chronic obstructive pulmonary disease	0.000141	0.000848	CcSEcCtD
Imatinib—Hypotension—Arformoterol—chronic obstructive pulmonary disease	0.00014	0.000845	CcSEcCtD
Imatinib—Hypotension—Formoterol—chronic obstructive pulmonary disease	0.00014	0.000845	CcSEcCtD
Imatinib—Pancreatitis—Prednisolone—chronic obstructive pulmonary disease	0.00014	0.000844	CcSEcCtD
Imatinib—Pruritus—Aminophylline—chronic obstructive pulmonary disease	0.000139	0.00084	CcSEcCtD
Imatinib—Shock—Salbutamol—chronic obstructive pulmonary disease	0.000139	0.00084	CcSEcCtD
Imatinib—Sweating increased—Prednisolone—chronic obstructive pulmonary disease	0.000139	0.000838	CcSEcCtD
Imatinib—Nervous system disorder—Salbutamol—chronic obstructive pulmonary disease	0.000139	0.000837	CcSEcCtD
Imatinib—Tachycardia—Salbutamol—chronic obstructive pulmonary disease	0.000138	0.000833	CcSEcCtD
Imatinib—Skin disorder—Salbutamol—chronic obstructive pulmonary disease	0.000137	0.000829	CcSEcCtD
Imatinib—Hypersensitivity—Tiotropium—chronic obstructive pulmonary disease	0.000137	0.000825	CcSEcCtD
Imatinib—Hyperhidrosis—Salbutamol—chronic obstructive pulmonary disease	0.000137	0.000825	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Arformoterol—chronic obstructive pulmonary disease	0.000137	0.000823	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Formoterol—chronic obstructive pulmonary disease	0.000137	0.000823	CcSEcCtD
Imatinib—Insomnia—Formoterol—chronic obstructive pulmonary disease	0.000136	0.000817	CcSEcCtD
Imatinib—Insomnia—Arformoterol—chronic obstructive pulmonary disease	0.000136	0.000817	CcSEcCtD
Imatinib—Anorexia—Salbutamol—chronic obstructive pulmonary disease	0.000135	0.000814	CcSEcCtD
Imatinib—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	0.000135	0.000813	CcSEcCtD
Imatinib—Vascular purpura—Prednisone—chronic obstructive pulmonary disease	0.000134	0.000809	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Montelukast—chronic obstructive pulmonary disease	0.000134	0.000807	CcSEcCtD
Imatinib—Dyspnoea—Formoterol—chronic obstructive pulmonary disease	0.000134	0.000806	CcSEcCtD
Imatinib—Dyspnoea—Arformoterol—chronic obstructive pulmonary disease	0.000134	0.000806	CcSEcCtD
Imatinib—Somnolence—Arformoterol—chronic obstructive pulmonary disease	0.000133	0.000804	CcSEcCtD
Imatinib—Somnolence—Formoterol—chronic obstructive pulmonary disease	0.000133	0.000804	CcSEcCtD
Imatinib—Insomnia—Montelukast—chronic obstructive pulmonary disease	0.000133	0.000801	CcSEcCtD
Imatinib—Cardiac failure congestive—Prednisone—chronic obstructive pulmonary disease	0.000132	0.000798	CcSEcCtD
Imatinib—Hypotension—Salbutamol—chronic obstructive pulmonary disease	0.000132	0.000797	CcSEcCtD
Imatinib—Dyspepsia—Formoterol—chronic obstructive pulmonary disease	0.000132	0.000796	CcSEcCtD
Imatinib—Dyspepsia—Arformoterol—chronic obstructive pulmonary disease	0.000132	0.000796	CcSEcCtD
Imatinib—Paraesthesia—Montelukast—chronic obstructive pulmonary disease	0.000132	0.000795	CcSEcCtD
Imatinib—Pruritus—Tiotropium—chronic obstructive pulmonary disease	0.000131	0.000792	CcSEcCtD
Imatinib—Somnolence—Montelukast—chronic obstructive pulmonary disease	0.00013	0.000787	CcSEcCtD
Imatinib—Dizziness—Aminophylline—chronic obstructive pulmonary disease	0.00013	0.000785	CcSEcCtD
Imatinib—Weight increased—Prednisolone—chronic obstructive pulmonary disease	0.00013	0.000783	CcSEcCtD
Imatinib—Gastrointestinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.000129	0.00078	CcSEcCtD
Imatinib—Gastrointestinal disorder—Formoterol—chronic obstructive pulmonary disease	0.000129	0.00078	CcSEcCtD
Imatinib—Dyspepsia—Montelukast—chronic obstructive pulmonary disease	0.000129	0.000779	CcSEcCtD
Imatinib—Fatigue—Arformoterol—chronic obstructive pulmonary disease	0.000129	0.000779	CcSEcCtD
Imatinib—Fatigue—Formoterol—chronic obstructive pulmonary disease	0.000129	0.000779	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Salbutamol—chronic obstructive pulmonary disease	0.000129	0.000778	CcSEcCtD
Imatinib—Pain—Formoterol—chronic obstructive pulmonary disease	0.000128	0.000773	CcSEcCtD
Imatinib—Constipation—Arformoterol—chronic obstructive pulmonary disease	0.000128	0.000773	CcSEcCtD
Imatinib—Constipation—Formoterol—chronic obstructive pulmonary disease	0.000128	0.000773	CcSEcCtD
Imatinib—Pain—Arformoterol—chronic obstructive pulmonary disease	0.000128	0.000773	CcSEcCtD
Imatinib—Insomnia—Salbutamol—chronic obstructive pulmonary disease	0.000128	0.000772	CcSEcCtD
Imatinib—Increased appetite—Prednisone—chronic obstructive pulmonary disease	0.000128	0.00077	CcSEcCtD
Imatinib—Paraesthesia—Salbutamol—chronic obstructive pulmonary disease	0.000127	0.000766	CcSEcCtD
Imatinib—Gastrointestinal disorder—Montelukast—chronic obstructive pulmonary disease	0.000127	0.000764	CcSEcCtD
Imatinib—Fatigue—Montelukast—chronic obstructive pulmonary disease	0.000127	0.000763	CcSEcCtD
Imatinib—Dyspnoea—Salbutamol—chronic obstructive pulmonary disease	0.000126	0.000761	CcSEcCtD
Imatinib—Somnolence—Salbutamol—chronic obstructive pulmonary disease	0.000126	0.000759	CcSEcCtD
Imatinib—Pain—Montelukast—chronic obstructive pulmonary disease	0.000126	0.000757	CcSEcCtD
Imatinib—Acute coronary syndrome—Prednisolone—chronic obstructive pulmonary disease	0.000125	0.000757	CcSEcCtD
Imatinib—Vomiting—Aminophylline—chronic obstructive pulmonary disease	0.000125	0.000755	CcSEcCtD
Imatinib—Neuropathy peripheral—Prednisolone—chronic obstructive pulmonary disease	0.000125	0.000752	CcSEcCtD
Imatinib—Myocardial infarction—Prednisolone—chronic obstructive pulmonary disease	0.000125	0.000752	CcSEcCtD
Imatinib—Dyspepsia—Salbutamol—chronic obstructive pulmonary disease	0.000125	0.000751	CcSEcCtD
Imatinib—Purpura—Prednisone—chronic obstructive pulmonary disease	0.000124	0.000751	CcSEcCtD
Imatinib—Rash—Aminophylline—chronic obstructive pulmonary disease	0.000124	0.000749	CcSEcCtD
Imatinib—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	0.000124	0.000748	CcSEcCtD
Imatinib—Conjunctivitis—Prednisolone—chronic obstructive pulmonary disease	0.000124	0.000746	CcSEcCtD
Imatinib—Feeling abnormal—Arformoterol—chronic obstructive pulmonary disease	0.000123	0.000745	CcSEcCtD
Imatinib—Feeling abnormal—Formoterol—chronic obstructive pulmonary disease	0.000123	0.000745	CcSEcCtD
Imatinib—Headache—Aminophylline—chronic obstructive pulmonary disease	0.000123	0.000744	CcSEcCtD
Imatinib—Decreased appetite—Salbutamol—chronic obstructive pulmonary disease	0.000123	0.000742	CcSEcCtD
Imatinib—Cardiac failure—Prednisone—chronic obstructive pulmonary disease	0.000123	0.000742	CcSEcCtD
Imatinib—Dizziness—Tiotropium—chronic obstructive pulmonary disease	0.000123	0.000741	CcSEcCtD
Imatinib—Gastrointestinal pain—Formoterol—chronic obstructive pulmonary disease	0.000123	0.000739	CcSEcCtD
Imatinib—Gastrointestinal pain—Arformoterol—chronic obstructive pulmonary disease	0.000123	0.000739	CcSEcCtD
Imatinib—Lethargy—Prednisone—chronic obstructive pulmonary disease	0.000122	0.000739	CcSEcCtD
Imatinib—Gastrointestinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.000122	0.000737	CcSEcCtD
Imatinib—Fatigue—Salbutamol—chronic obstructive pulmonary disease	0.000122	0.000736	CcSEcCtD
Imatinib—Pain—Salbutamol—chronic obstructive pulmonary disease	0.000121	0.00073	CcSEcCtD
Imatinib—Constipation—Salbutamol—chronic obstructive pulmonary disease	0.000121	0.00073	CcSEcCtD
Imatinib—Gastrointestinal pain—Montelukast—chronic obstructive pulmonary disease	0.00012	0.000724	CcSEcCtD
Imatinib—Gastrointestinal haemorrhage—Prednisone—chronic obstructive pulmonary disease	0.00012	0.000724	CcSEcCtD
Imatinib—Urticaria—Arformoterol—chronic obstructive pulmonary disease	0.000119	0.000718	CcSEcCtD
Imatinib—Urticaria—Formoterol—chronic obstructive pulmonary disease	0.000119	0.000718	CcSEcCtD
Imatinib—ABCB1—lung—chronic obstructive pulmonary disease	0.000118	0.00151	CbGeAlD
Imatinib—Body temperature increased—Arformoterol—chronic obstructive pulmonary disease	0.000118	0.000714	CcSEcCtD
Imatinib—Abdominal pain—Formoterol—chronic obstructive pulmonary disease	0.000118	0.000714	CcSEcCtD
Imatinib—Body temperature increased—Formoterol—chronic obstructive pulmonary disease	0.000118	0.000714	CcSEcCtD
Imatinib—Abdominal pain—Arformoterol—chronic obstructive pulmonary disease	0.000118	0.000714	CcSEcCtD
Imatinib—Vomiting—Tiotropium—chronic obstructive pulmonary disease	0.000118	0.000712	CcSEcCtD
Imatinib—Rash—Tiotropium—chronic obstructive pulmonary disease	0.000117	0.000706	CcSEcCtD
Imatinib—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	0.000117	0.000705	CcSEcCtD
Imatinib—Nausea—Aminophylline—chronic obstructive pulmonary disease	0.000117	0.000705	CcSEcCtD
Imatinib—Urticaria—Montelukast—chronic obstructive pulmonary disease	0.000117	0.000703	CcSEcCtD
Imatinib—Feeling abnormal—Salbutamol—chronic obstructive pulmonary disease	0.000117	0.000703	CcSEcCtD
Imatinib—Headache—Tiotropium—chronic obstructive pulmonary disease	0.000116	0.000702	CcSEcCtD
Imatinib—Abdominal pain—Montelukast—chronic obstructive pulmonary disease	0.000116	0.0007	CcSEcCtD
Imatinib—Body temperature increased—Montelukast—chronic obstructive pulmonary disease	0.000116	0.0007	CcSEcCtD
Imatinib—Face oedema—Prednisone—chronic obstructive pulmonary disease	0.000116	0.000699	CcSEcCtD
Imatinib—Gastrointestinal pain—Salbutamol—chronic obstructive pulmonary disease	0.000116	0.000698	CcSEcCtD
Imatinib—Haemoglobin—Prednisolone—chronic obstructive pulmonary disease	0.000115	0.000692	CcSEcCtD
Imatinib—Haemorrhage—Prednisolone—chronic obstructive pulmonary disease	0.000114	0.000689	CcSEcCtD
Imatinib—Cardiac arrest—Prednisone—chronic obstructive pulmonary disease	0.000114	0.000688	CcSEcCtD
Imatinib—Urticaria—Salbutamol—chronic obstructive pulmonary disease	0.000112	0.000678	CcSEcCtD
Imatinib—Abdominal pain—Salbutamol—chronic obstructive pulmonary disease	0.000112	0.000675	CcSEcCtD
Imatinib—Body temperature increased—Salbutamol—chronic obstructive pulmonary disease	0.000112	0.000675	CcSEcCtD
Imatinib—Hypersensitivity—Formoterol—chronic obstructive pulmonary disease	0.00011	0.000666	CcSEcCtD
Imatinib—Hypersensitivity—Arformoterol—chronic obstructive pulmonary disease	0.00011	0.000666	CcSEcCtD
Imatinib—Nausea—Tiotropium—chronic obstructive pulmonary disease	0.00011	0.000665	CcSEcCtD
Imatinib—Dry skin—Prednisone—chronic obstructive pulmonary disease	0.00011	0.000663	CcSEcCtD
Imatinib—Hypokalaemia—Prednisone—chronic obstructive pulmonary disease	0.000109	0.000659	CcSEcCtD
Imatinib—Hypersensitivity—Montelukast—chronic obstructive pulmonary disease	0.000108	0.000652	CcSEcCtD
Imatinib—Asthenia—Formoterol—chronic obstructive pulmonary disease	0.000108	0.000648	CcSEcCtD
Imatinib—Asthenia—Arformoterol—chronic obstructive pulmonary disease	0.000108	0.000648	CcSEcCtD
Imatinib—Pruritus—Arformoterol—chronic obstructive pulmonary disease	0.000106	0.000639	CcSEcCtD
Imatinib—Pruritus—Formoterol—chronic obstructive pulmonary disease	0.000106	0.000639	CcSEcCtD
Imatinib—Alanine aminotransferase increased—Prednisone—chronic obstructive pulmonary disease	0.000106	0.000638	CcSEcCtD
Imatinib—Muscular weakness—Prednisone—chronic obstructive pulmonary disease	0.000106	0.000638	CcSEcCtD
Imatinib—Asthenia—Montelukast—chronic obstructive pulmonary disease	0.000105	0.000635	CcSEcCtD
Imatinib—Abdominal distension—Prednisone—chronic obstructive pulmonary disease	0.000104	0.00063	CcSEcCtD
Imatinib—Hypersensitivity—Salbutamol—chronic obstructive pulmonary disease	0.000104	0.000629	CcSEcCtD
Imatinib—Pruritus—Montelukast—chronic obstructive pulmonary disease	0.000104	0.000626	CcSEcCtD
Imatinib—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	0.000103	0.000618	CcSEcCtD
Imatinib—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	0.000103	0.000618	CcSEcCtD
Imatinib—Arrhythmia—Prednisolone—chronic obstructive pulmonary disease	0.000102	0.000615	CcSEcCtD
Imatinib—Pancreatitis—Prednisone—chronic obstructive pulmonary disease	0.000102	0.000613	CcSEcCtD
Imatinib—Asthenia—Salbutamol—chronic obstructive pulmonary disease	0.000102	0.000612	CcSEcCtD
Imatinib—Sweating increased—Prednisone—chronic obstructive pulmonary disease	0.000101	0.000609	CcSEcCtD
Imatinib—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	0.0001	0.000606	CcSEcCtD
Imatinib—Pruritus—Salbutamol—chronic obstructive pulmonary disease	0.0001	0.000604	CcSEcCtD
Imatinib—Erythema—Prednisolone—chronic obstructive pulmonary disease	9.94e-05	0.0006	CcSEcCtD
Imatinib—Dizziness—Formoterol—chronic obstructive pulmonary disease	9.91e-05	0.000598	CcSEcCtD
Imatinib—Dizziness—Arformoterol—chronic obstructive pulmonary disease	9.91e-05	0.000598	CcSEcCtD
Imatinib—Dizziness—Montelukast—chronic obstructive pulmonary disease	9.7e-05	0.000585	CcSEcCtD
Imatinib—Neutropenia—Prednisone—chronic obstructive pulmonary disease	9.7e-05	0.000585	CcSEcCtD
Imatinib—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	9.68e-05	0.000584	CcSEcCtD
Imatinib—Erectile dysfunction—Prednisone—chronic obstructive pulmonary disease	9.55e-05	0.000576	CcSEcCtD
Imatinib—Vomiting—Formoterol—chronic obstructive pulmonary disease	9.53e-05	0.000575	CcSEcCtD
Imatinib—Vomiting—Arformoterol—chronic obstructive pulmonary disease	9.53e-05	0.000575	CcSEcCtD
Imatinib—Rash—Arformoterol—chronic obstructive pulmonary disease	9.45e-05	0.00057	CcSEcCtD
Imatinib—Rash—Formoterol—chronic obstructive pulmonary disease	9.45e-05	0.00057	CcSEcCtD
Imatinib—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	9.44e-05	0.000569	CcSEcCtD
Imatinib—Dermatitis—Formoterol—chronic obstructive pulmonary disease	9.44e-05	0.000569	CcSEcCtD
Imatinib—Weight increased—Prednisone—chronic obstructive pulmonary disease	9.44e-05	0.000569	CcSEcCtD
Imatinib—Headache—Arformoterol—chronic obstructive pulmonary disease	9.39e-05	0.000566	CcSEcCtD
Imatinib—Headache—Formoterol—chronic obstructive pulmonary disease	9.39e-05	0.000566	CcSEcCtD
Imatinib—Weight decreased—Prednisone—chronic obstructive pulmonary disease	9.38e-05	0.000566	CcSEcCtD
Imatinib—Vision blurred—Prednisolone—chronic obstructive pulmonary disease	9.37e-05	0.000565	CcSEcCtD
Imatinib—Dizziness—Salbutamol—chronic obstructive pulmonary disease	9.36e-05	0.000564	CcSEcCtD
Imatinib—Hyperglycaemia—Prednisone—chronic obstructive pulmonary disease	9.35e-05	0.000564	CcSEcCtD
Imatinib—Vomiting—Montelukast—chronic obstructive pulmonary disease	9.33e-05	0.000563	CcSEcCtD
Imatinib—Rash—Montelukast—chronic obstructive pulmonary disease	9.25e-05	0.000558	CcSEcCtD
Imatinib—Dermatitis—Montelukast—chronic obstructive pulmonary disease	9.24e-05	0.000558	CcSEcCtD
Imatinib—Ill-defined disorder—Prednisolone—chronic obstructive pulmonary disease	9.23e-05	0.000556	CcSEcCtD
Imatinib—Depression—Prednisone—chronic obstructive pulmonary disease	9.22e-05	0.000556	CcSEcCtD
Imatinib—Headache—Montelukast—chronic obstructive pulmonary disease	9.19e-05	0.000555	CcSEcCtD
Imatinib—Acute coronary syndrome—Prednisone—chronic obstructive pulmonary disease	9.11e-05	0.00055	CcSEcCtD
Imatinib—Angioedema—Prednisolone—chronic obstructive pulmonary disease	9.09e-05	0.000548	CcSEcCtD
Imatinib—Myocardial infarction—Prednisone—chronic obstructive pulmonary disease	9.06e-05	0.000547	CcSEcCtD
Imatinib—Neuropathy peripheral—Prednisone—chronic obstructive pulmonary disease	9.06e-05	0.000547	CcSEcCtD
Imatinib—Vomiting—Salbutamol—chronic obstructive pulmonary disease	9e-05	0.000543	CcSEcCtD
Imatinib—Malaise—Prednisolone—chronic obstructive pulmonary disease	8.97e-05	0.000541	CcSEcCtD
Imatinib—Vertigo—Prednisolone—chronic obstructive pulmonary disease	8.93e-05	0.000539	CcSEcCtD
Imatinib—Rash—Salbutamol—chronic obstructive pulmonary disease	8.92e-05	0.000538	CcSEcCtD
Imatinib—Syncope—Prednisolone—chronic obstructive pulmonary disease	8.92e-05	0.000538	CcSEcCtD
Imatinib—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	8.91e-05	0.000538	CcSEcCtD
Imatinib—Nausea—Formoterol—chronic obstructive pulmonary disease	8.9e-05	0.000537	CcSEcCtD
Imatinib—Nausea—Arformoterol—chronic obstructive pulmonary disease	8.9e-05	0.000537	CcSEcCtD
Imatinib—Headache—Salbutamol—chronic obstructive pulmonary disease	8.86e-05	0.000535	CcSEcCtD
Imatinib—Loss of consciousness—Prednisolone—chronic obstructive pulmonary disease	8.74e-05	0.000527	CcSEcCtD
Imatinib—Nausea—Montelukast—chronic obstructive pulmonary disease	8.72e-05	0.000526	CcSEcCtD
Imatinib—Convulsion—Prednisolone—chronic obstructive pulmonary disease	8.61e-05	0.00052	CcSEcCtD
Imatinib—Hypertension—Prednisolone—chronic obstructive pulmonary disease	8.58e-05	0.000518	CcSEcCtD
Imatinib—Nausea—Salbutamol—chronic obstructive pulmonary disease	8.4e-05	0.000507	CcSEcCtD
Imatinib—Discomfort—Prednisolone—chronic obstructive pulmonary disease	8.36e-05	0.000504	CcSEcCtD
Imatinib—Haemoglobin—Prednisone—chronic obstructive pulmonary disease	8.34e-05	0.000503	CcSEcCtD
Imatinib—Haemorrhage—Prednisone—chronic obstructive pulmonary disease	8.3e-05	0.000501	CcSEcCtD
Imatinib—Connective tissue disorder—Prednisone—chronic obstructive pulmonary disease	8.16e-05	0.000492	CcSEcCtD
Imatinib—Oedema—Prednisolone—chronic obstructive pulmonary disease	8.11e-05	0.000489	CcSEcCtD
Imatinib—Anaphylactic shock—Prednisolone—chronic obstructive pulmonary disease	8.11e-05	0.000489	CcSEcCtD
Imatinib—Shock—Prednisolone—chronic obstructive pulmonary disease	7.98e-05	0.000482	CcSEcCtD
Imatinib—Tachycardia—Prednisolone—chronic obstructive pulmonary disease	7.92e-05	0.000478	CcSEcCtD
Imatinib—Hyperhidrosis—Prednisolone—chronic obstructive pulmonary disease	7.84e-05	0.000473	CcSEcCtD
Imatinib—Eye disorder—Prednisone—chronic obstructive pulmonary disease	7.76e-05	0.000468	CcSEcCtD
Imatinib—Flushing—Prednisone—chronic obstructive pulmonary disease	7.7e-05	0.000465	CcSEcCtD
Imatinib—Angiopathy—Prednisone—chronic obstructive pulmonary disease	7.53e-05	0.000454	CcSEcCtD
Imatinib—Immune system disorder—Prednisone—chronic obstructive pulmonary disease	7.5e-05	0.000452	CcSEcCtD
Imatinib—Arrhythmia—Prednisone—chronic obstructive pulmonary disease	7.41e-05	0.000447	CcSEcCtD
Imatinib—Insomnia—Prednisolone—chronic obstructive pulmonary disease	7.34e-05	0.000443	CcSEcCtD
Imatinib—Alopecia—Prednisone—chronic obstructive pulmonary disease	7.33e-05	0.000442	CcSEcCtD
Imatinib—Paraesthesia—Prednisolone—chronic obstructive pulmonary disease	7.29e-05	0.00044	CcSEcCtD
Imatinib—Mental disorder—Prednisone—chronic obstructive pulmonary disease	7.27e-05	0.000439	CcSEcCtD
Imatinib—Erythema—Prednisone—chronic obstructive pulmonary disease	7.23e-05	0.000436	CcSEcCtD
Imatinib—Malnutrition—Prednisone—chronic obstructive pulmonary disease	7.23e-05	0.000436	CcSEcCtD
Imatinib—Pain—Prednisolone—chronic obstructive pulmonary disease	6.94e-05	0.000419	CcSEcCtD
Imatinib—Vision blurred—Prednisone—chronic obstructive pulmonary disease	6.81e-05	0.000411	CcSEcCtD
Imatinib—Ill-defined disorder—Prednisone—chronic obstructive pulmonary disease	6.7e-05	0.000404	CcSEcCtD
Imatinib—Feeling abnormal—Prednisolone—chronic obstructive pulmonary disease	6.69e-05	0.000403	CcSEcCtD
Imatinib—Anaemia—Prednisone—chronic obstructive pulmonary disease	6.68e-05	0.000403	CcSEcCtD
Imatinib—Angioedema—Prednisone—chronic obstructive pulmonary disease	6.6e-05	0.000398	CcSEcCtD
Imatinib—Malaise—Prednisone—chronic obstructive pulmonary disease	6.52e-05	0.000393	CcSEcCtD
Imatinib—Vertigo—Prednisone—chronic obstructive pulmonary disease	6.49e-05	0.000392	CcSEcCtD
Imatinib—Syncope—Prednisone—chronic obstructive pulmonary disease	6.48e-05	0.000391	CcSEcCtD
Imatinib—Urticaria—Prednisolone—chronic obstructive pulmonary disease	6.45e-05	0.000389	CcSEcCtD
Imatinib—Loss of consciousness—Prednisone—chronic obstructive pulmonary disease	6.35e-05	0.000383	CcSEcCtD
Imatinib—Convulsion—Prednisone—chronic obstructive pulmonary disease	6.26e-05	0.000378	CcSEcCtD
Imatinib—Hypertension—Prednisone—chronic obstructive pulmonary disease	6.24e-05	0.000376	CcSEcCtD
Imatinib—Arthralgia—Prednisone—chronic obstructive pulmonary disease	6.15e-05	0.000371	CcSEcCtD
Imatinib—Myalgia—Prednisone—chronic obstructive pulmonary disease	6.15e-05	0.000371	CcSEcCtD
Imatinib—Anxiety—Prednisone—chronic obstructive pulmonary disease	6.13e-05	0.00037	CcSEcCtD
Imatinib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—chronic obstructive pulmonary disease	6.11e-05	0.000368	CcSEcCtD
Imatinib—Discomfort—Prednisone—chronic obstructive pulmonary disease	6.08e-05	0.000367	CcSEcCtD
Imatinib—Hypersensitivity—Prednisolone—chronic obstructive pulmonary disease	5.98e-05	0.000361	CcSEcCtD
Imatinib—Anaphylactic shock—Prednisone—chronic obstructive pulmonary disease	5.9e-05	0.000356	CcSEcCtD
Imatinib—Oedema—Prednisone—chronic obstructive pulmonary disease	5.9e-05	0.000356	CcSEcCtD
Imatinib—Infection—Prednisone—chronic obstructive pulmonary disease	5.86e-05	0.000353	CcSEcCtD
Imatinib—Shock—Prednisone—chronic obstructive pulmonary disease	5.8e-05	0.00035	CcSEcCtD
Imatinib—Nervous system disorder—Prednisone—chronic obstructive pulmonary disease	5.78e-05	0.000349	CcSEcCtD
Imatinib—Tachycardia—Prednisone—chronic obstructive pulmonary disease	5.75e-05	0.000347	CcSEcCtD
Imatinib—Skin disorder—Prednisone—chronic obstructive pulmonary disease	5.73e-05	0.000345	CcSEcCtD
Imatinib—Hyperhidrosis—Prednisone—chronic obstructive pulmonary disease	5.7e-05	0.000344	CcSEcCtD
Imatinib—Anorexia—Prednisone—chronic obstructive pulmonary disease	5.62e-05	0.000339	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Prednisone—chronic obstructive pulmonary disease	5.37e-05	0.000324	CcSEcCtD
Imatinib—Dizziness—Prednisolone—chronic obstructive pulmonary disease	5.37e-05	0.000324	CcSEcCtD
Imatinib—Insomnia—Prednisone—chronic obstructive pulmonary disease	5.33e-05	0.000322	CcSEcCtD
Imatinib—Paraesthesia—Prednisone—chronic obstructive pulmonary disease	5.29e-05	0.000319	CcSEcCtD
Imatinib—Dyspepsia—Prednisone—chronic obstructive pulmonary disease	5.19e-05	0.000313	CcSEcCtD
Imatinib—Decreased appetite—Prednisone—chronic obstructive pulmonary disease	5.13e-05	0.000309	CcSEcCtD
Imatinib—Rash—Prednisolone—chronic obstructive pulmonary disease	5.12e-05	0.000309	CcSEcCtD
Imatinib—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	5.11e-05	0.000308	CcSEcCtD
Imatinib—Fatigue—Prednisone—chronic obstructive pulmonary disease	5.08e-05	0.000307	CcSEcCtD
Imatinib—Headache—Prednisolone—chronic obstructive pulmonary disease	5.08e-05	0.000307	CcSEcCtD
Imatinib—Constipation—Prednisone—chronic obstructive pulmonary disease	5.04e-05	0.000304	CcSEcCtD
Imatinib—Feeling abnormal—Prednisone—chronic obstructive pulmonary disease	4.86e-05	0.000293	CcSEcCtD
Imatinib—Gastrointestinal pain—Prednisone—chronic obstructive pulmonary disease	4.82e-05	0.000291	CcSEcCtD
Imatinib—Nausea—Prednisolone—chronic obstructive pulmonary disease	4.82e-05	0.000291	CcSEcCtD
Imatinib—Urticaria—Prednisone—chronic obstructive pulmonary disease	4.68e-05	0.000283	CcSEcCtD
Imatinib—Abdominal pain—Prednisone—chronic obstructive pulmonary disease	4.66e-05	0.000281	CcSEcCtD
Imatinib—Body temperature increased—Prednisone—chronic obstructive pulmonary disease	4.66e-05	0.000281	CcSEcCtD
Imatinib—Hypersensitivity—Prednisone—chronic obstructive pulmonary disease	4.34e-05	0.000262	CcSEcCtD
Imatinib—Asthenia—Prednisone—chronic obstructive pulmonary disease	4.23e-05	0.000255	CcSEcCtD
Imatinib—Pruritus—Prednisone—chronic obstructive pulmonary disease	4.17e-05	0.000252	CcSEcCtD
Imatinib—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	4.03e-05	0.000243	CcSEcCtD
Imatinib—Dizziness—Prednisone—chronic obstructive pulmonary disease	3.9e-05	0.000235	CcSEcCtD
Imatinib—Vomiting—Prednisone—chronic obstructive pulmonary disease	3.75e-05	0.000226	CcSEcCtD
Imatinib—Rash—Prednisone—chronic obstructive pulmonary disease	3.72e-05	0.000224	CcSEcCtD
Imatinib—Dermatitis—Prednisone—chronic obstructive pulmonary disease	3.71e-05	0.000224	CcSEcCtD
Imatinib—Headache—Prednisone—chronic obstructive pulmonary disease	3.69e-05	0.000223	CcSEcCtD
Imatinib—Nausea—Prednisone—chronic obstructive pulmonary disease	3.5e-05	0.000211	CcSEcCtD
Imatinib—PDGFRA—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	9.75e-06	0.000105	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—CYP1A2—chronic obstructive pulmonary disease	9.71e-06	0.000104	CbGpPWpGaD
Imatinib—ALB—Platelet activation, signaling and aggregation—TGFB1—chronic obstructive pulmonary disease	9.71e-06	0.000104	CbGpPWpGaD
Imatinib—ABL1—Developmental Biology—TNF—chronic obstructive pulmonary disease	9.68e-06	0.000104	CbGpPWpGaD
Imatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—chronic obstructive pulmonary disease	9.56e-06	0.000103	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	9.52e-06	0.000102	CbGpPWpGaD
Imatinib—PDGFRB—Disease—NOS2—chronic obstructive pulmonary disease	9.5e-06	0.000102	CbGpPWpGaD
Imatinib—ALB—Hemostasis—NOS2—chronic obstructive pulmonary disease	9.42e-06	0.000101	CbGpPWpGaD
Imatinib—KIT—Disease—SERPINE1—chronic obstructive pulmonary disease	9.39e-06	0.000101	CbGpPWpGaD
Imatinib—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—chronic obstructive pulmonary disease	9.38e-06	0.000101	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	9.36e-06	0.000101	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	9.31e-06	0.0001	CbGpPWpGaD
Imatinib—PDGFRB—Innate Immune System—EGFR—chronic obstructive pulmonary disease	9.21e-06	9.91e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	9.19e-06	9.89e-05	CbGpPWpGaD
Imatinib—LCK—Disease—ERBB3—chronic obstructive pulmonary disease	9.15e-06	9.84e-05	CbGpPWpGaD
Imatinib—LCK—Hemostasis—VEGFA—chronic obstructive pulmonary disease	9.13e-06	9.81e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—GSTT1—chronic obstructive pulmonary disease	9.08e-06	9.76e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—CRP—chronic obstructive pulmonary disease	9.06e-06	9.74e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	9.01e-06	9.69e-05	CbGpPWpGaD
Imatinib—ABL1—Innate Immune System—EGFR—chronic obstructive pulmonary disease	8.98e-06	9.66e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—GCLC—chronic obstructive pulmonary disease	8.97e-06	9.65e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	8.97e-06	9.65e-05	CbGpPWpGaD
Imatinib—KIT—Disease—NOS3—chronic obstructive pulmonary disease	8.96e-06	9.64e-05	CbGpPWpGaD
Imatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—chronic obstructive pulmonary disease	8.93e-06	9.6e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—SERPINE1—chronic obstructive pulmonary disease	8.88e-06	9.55e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	8.86e-06	9.53e-05	CbGpPWpGaD
Imatinib—PDGFRB—Adaptive Immune System—EGFR—chronic obstructive pulmonary disease	8.85e-06	9.51e-05	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—GSTP1—chronic obstructive pulmonary disease	8.78e-06	9.45e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	8.78e-06	9.45e-05	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—GSTP1—chronic obstructive pulmonary disease	8.71e-06	9.36e-05	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—GSTP1—chronic obstructive pulmonary disease	8.69e-06	9.35e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—TLR4—chronic obstructive pulmonary disease	8.69e-06	9.34e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	8.68e-06	9.33e-05	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—HMOX1—chronic obstructive pulmonary disease	8.66e-06	9.32e-05	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—HMOX1—chronic obstructive pulmonary disease	8.59e-06	9.23e-05	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—HMOX1—chronic obstructive pulmonary disease	8.57e-06	9.22e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	8.56e-06	9.21e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—KL—chronic obstructive pulmonary disease	8.55e-06	9.19e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	8.53e-06	9.17e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—NOS3—chronic obstructive pulmonary disease	8.48e-06	9.12e-05	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—GSTP1—chronic obstructive pulmonary disease	8.44e-06	9.08e-05	CbGpPWpGaD
Imatinib—LCK—Hemostasis—TGFB1—chronic obstructive pulmonary disease	8.38e-06	9.01e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—LEP—chronic obstructive pulmonary disease	8.38e-06	9.01e-05	CbGpPWpGaD
Imatinib—ABL1—Hemostasis—TP53—chronic obstructive pulmonary disease	8.37e-06	9.01e-05	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—HMOX1—chronic obstructive pulmonary disease	8.32e-06	8.95e-05	CbGpPWpGaD
Imatinib—KIT—Innate Immune System—IL6—chronic obstructive pulmonary disease	8.3e-06	8.93e-05	CbGpPWpGaD
Imatinib—KIT—Immune System—IL1B—chronic obstructive pulmonary disease	8.26e-06	8.88e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—CTGF—chronic obstructive pulmonary disease	8.19e-06	8.81e-05	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—GSTP1—chronic obstructive pulmonary disease	8.1e-06	8.71e-05	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—GSTM1—chronic obstructive pulmonary disease	8.07e-06	8.68e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—SERPINE1—chronic obstructive pulmonary disease	8e-06	8.61e-05	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—GSTM1—chronic obstructive pulmonary disease	8e-06	8.6e-05	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—HMOX1—chronic obstructive pulmonary disease	7.99e-06	8.59e-05	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—GSTM1—chronic obstructive pulmonary disease	7.99e-06	8.59e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	7.98e-06	8.59e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	7.94e-06	8.54e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—SERPINE1—chronic obstructive pulmonary disease	7.93e-06	8.53e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—LEP—chronic obstructive pulmonary disease	7.93e-06	8.53e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	7.89e-06	8.48e-05	CbGpPWpGaD
Imatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—chronic obstructive pulmonary disease	7.87e-06	8.47e-05	CbGpPWpGaD
Imatinib—PDGFRA—Innate Immune System—IL6—chronic obstructive pulmonary disease	7.86e-06	8.45e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—GSTT1—chronic obstructive pulmonary disease	7.82e-06	8.41e-05	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—IL1B—chronic obstructive pulmonary disease	7.82e-06	8.41e-05	CbGpPWpGaD
Imatinib—ABL1—Developmental Biology—IL6—chronic obstructive pulmonary disease	7.81e-06	8.4e-05	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—GSTM1—chronic obstructive pulmonary disease	7.75e-06	8.34e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—GCLC—chronic obstructive pulmonary disease	7.73e-06	8.31e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—GC—chronic obstructive pulmonary disease	7.73e-06	8.31e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	7.68e-06	8.26e-05	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—CYP1A1—chronic obstructive pulmonary disease	7.65e-06	8.23e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—NOS3—chronic obstructive pulmonary disease	7.64e-06	8.22e-05	CbGpPWpGaD
Imatinib—LCK—Disease—NOS2—chronic obstructive pulmonary disease	7.63e-06	8.2e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	7.6e-06	8.17e-05	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—CYP1A1—chronic obstructive pulmonary disease	7.58e-06	8.16e-05	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—CYP1A1—chronic obstructive pulmonary disease	7.57e-06	8.14e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—NOS3—chronic obstructive pulmonary disease	7.57e-06	8.14e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—CYP1A2—chronic obstructive pulmonary disease	7.55e-06	8.11e-05	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—GSTM1—chronic obstructive pulmonary disease	7.45e-06	8.01e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	7.42e-06	7.98e-05	CbGpPWpGaD
Imatinib—LCK—Innate Immune System—EGFR—chronic obstructive pulmonary disease	7.39e-06	7.95e-05	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—CYP1A1—chronic obstructive pulmonary disease	7.35e-06	7.91e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	7.18e-06	7.73e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—LEP—chronic obstructive pulmonary disease	7.14e-06	7.68e-05	CbGpPWpGaD
Imatinib—LCK—Adaptive Immune System—EGFR—chronic obstructive pulmonary disease	7.1e-06	7.64e-05	CbGpPWpGaD
Imatinib—PDGFRB—Innate Immune System—IL6—chronic obstructive pulmonary disease	7.08e-06	7.62e-05	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—CYP1A1—chronic obstructive pulmonary disease	7.06e-06	7.59e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—CTGF—chronic obstructive pulmonary disease	7.05e-06	7.59e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	7.05e-06	7.58e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—IL1B—chronic obstructive pulmonary disease	7.04e-06	7.57e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—GSTT1—chronic obstructive pulmonary disease	7.02e-06	7.55e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—GCLC—chronic obstructive pulmonary disease	6.94e-06	7.46e-05	CbGpPWpGaD
Imatinib—ABL1—Innate Immune System—IL6—chronic obstructive pulmonary disease	6.9e-06	7.42e-05	CbGpPWpGaD
Imatinib—LCK—Hemostasis—TP53—chronic obstructive pulmonary disease	6.9e-06	7.42e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	6.87e-06	7.39e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—IL1B—chronic obstructive pulmonary disease	6.86e-06	7.38e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—GSTT1—chronic obstructive pulmonary disease	6.85e-06	7.37e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—GCLC—chronic obstructive pulmonary disease	6.77e-06	7.28e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	6.57e-06	7.07e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—CYP1A2—chronic obstructive pulmonary disease	6.5e-06	6.99e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	6.47e-06	6.96e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—GSTT1—chronic obstructive pulmonary disease	6.46e-06	6.94e-05	CbGpPWpGaD
Imatinib—LCK—Disease—SERPINE1—chronic obstructive pulmonary disease	6.42e-06	6.91e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	6.41e-06	6.89e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—GSTT1—chronic obstructive pulmonary disease	6.4e-06	6.88e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—GCLC—chronic obstructive pulmonary disease	6.38e-06	6.86e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—CTGF—chronic obstructive pulmonary disease	6.33e-06	6.81e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—GCLC—chronic obstructive pulmonary disease	6.33e-06	6.8e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—GSTP1—chronic obstructive pulmonary disease	6.29e-06	6.77e-05	CbGpPWpGaD
Imatinib—KIT—Immune System—EGFR—chronic obstructive pulmonary disease	6.29e-06	6.77e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	6.27e-06	6.75e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	6.22e-06	6.69e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—HMOX1—chronic obstructive pulmonary disease	6.21e-06	6.67e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—CTGF—chronic obstructive pulmonary disease	6.18e-06	6.65e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	6.17e-06	6.64e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	6.17e-06	6.63e-05	CbGpPWpGaD
Imatinib—LCK—Disease—NOS3—chronic obstructive pulmonary disease	6.13e-06	6.6e-05	CbGpPWpGaD
Imatinib—ABCB1—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	6e-06	6.46e-05	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—EGFR—chronic obstructive pulmonary disease	5.96e-06	6.41e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	5.94e-06	6.39e-05	CbGpPWpGaD
Imatinib—KIT—Disease—TGFB1—chronic obstructive pulmonary disease	5.93e-06	6.37e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	5.9e-06	6.34e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—CYP1A2—chronic obstructive pulmonary disease	5.83e-06	6.27e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—CTGF—chronic obstructive pulmonary disease	5.82e-06	6.26e-05	CbGpPWpGaD
Imatinib—KIT—Disease—EGFR—chronic obstructive pulmonary disease	5.81e-06	6.25e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—GSTM1—chronic obstructive pulmonary disease	5.78e-06	6.22e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—CTGF—chronic obstructive pulmonary disease	5.77e-06	6.21e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—LEP—chronic obstructive pulmonary disease	5.73e-06	6.16e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—CYP1A2—chronic obstructive pulmonary disease	5.69e-06	6.12e-05	CbGpPWpGaD
Imatinib—LCK—Innate Immune System—IL6—chronic obstructive pulmonary disease	5.68e-06	6.11e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	5.66e-06	6.09e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—IL1B—chronic obstructive pulmonary disease	5.65e-06	6.08e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—TGFB1—chronic obstructive pulmonary disease	5.61e-06	6.03e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	5.6e-06	6.03e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	5.57e-06	5.99e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	5.55e-06	5.97e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—EGFR—chronic obstructive pulmonary disease	5.5e-06	5.91e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—CYP1A1—chronic obstructive pulmonary disease	5.48e-06	5.9e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—GSTT1—chronic obstructive pulmonary disease	5.47e-06	5.88e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—VEGFA—chronic obstructive pulmonary disease	5.46e-06	5.87e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—GSTP1—chronic obstructive pulmonary disease	5.42e-06	5.83e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—GCLC—chronic obstructive pulmonary disease	5.41e-06	5.81e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—EGFR—chronic obstructive pulmonary disease	5.37e-06	5.77e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—CYP1A2—chronic obstructive pulmonary disease	5.37e-06	5.77e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	5.35e-06	5.76e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—HMOX1—chronic obstructive pulmonary disease	5.35e-06	5.75e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—CYP1A2—chronic obstructive pulmonary disease	5.32e-06	5.72e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	5.27e-06	5.67e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—EGFR—chronic obstructive pulmonary disease	5.23e-06	5.62e-05	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—ALB—chronic obstructive pulmonary disease	5.2e-06	5.59e-05	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—ALB—chronic obstructive pulmonary disease	5.16e-06	5.54e-05	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—ALB—chronic obstructive pulmonary disease	5.15e-06	5.54e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—TGFB1—chronic obstructive pulmonary disease	5.05e-06	5.43e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	5.04e-06	5.42e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	5.03e-06	5.41e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—TGFB1—chronic obstructive pulmonary disease	5.01e-06	5.38e-05	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—ALB—chronic obstructive pulmonary disease	5e-06	5.37e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—GSTM1—chronic obstructive pulmonary disease	4.98e-06	5.36e-05	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—NOS3—chronic obstructive pulmonary disease	4.98e-06	5.35e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—EGFR—chronic obstructive pulmonary disease	4.95e-06	5.33e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—CTGF—chronic obstructive pulmonary disease	4.93e-06	5.31e-05	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—NOS3—chronic obstructive pulmonary disease	4.93e-06	5.3e-05	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—NOS3—chronic obstructive pulmonary disease	4.92e-06	5.3e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—GSTP1—chronic obstructive pulmonary disease	4.87e-06	5.23e-05	CbGpPWpGaD
Imatinib—KIT—Immune System—IL6—chronic obstructive pulmonary disease	4.84e-06	5.2e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—HMOX1—chronic obstructive pulmonary disease	4.8e-06	5.16e-05	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—ALB—chronic obstructive pulmonary disease	4.8e-06	5.16e-05	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—NOS3—chronic obstructive pulmonary disease	4.78e-06	5.14e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	4.77e-06	5.13e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—GSTP1—chronic obstructive pulmonary disease	4.75e-06	5.11e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	4.75e-06	5.1e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—CYP1A1—chronic obstructive pulmonary disease	4.72e-06	5.08e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—HMOX1—chronic obstructive pulmonary disease	4.68e-06	5.04e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—TP53—chronic obstructive pulmonary disease	4.66e-06	5.01e-05	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—NOS3—chronic obstructive pulmonary disease	4.59e-06	4.94e-05	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—IL6—chronic obstructive pulmonary disease	4.58e-06	4.92e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	4.52e-06	4.86e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	4.5e-06	4.84e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—GSTP1—chronic obstructive pulmonary disease	4.47e-06	4.81e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—GSTM1—chronic obstructive pulmonary disease	4.47e-06	4.81e-05	CbGpPWpGaD
Imatinib—KIT—Disease—IL6—chronic obstructive pulmonary disease	4.46e-06	4.8e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—GSTP1—chronic obstructive pulmonary disease	4.44e-06	4.77e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—HMOX1—chronic obstructive pulmonary disease	4.41e-06	4.75e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—HMOX1—chronic obstructive pulmonary disease	4.38e-06	4.71e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—GSTM1—chronic obstructive pulmonary disease	4.36e-06	4.69e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—EGFR—chronic obstructive pulmonary disease	4.31e-06	4.63e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	4.29e-06	4.62e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	4.29e-06	4.62e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	4.28e-06	4.6e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—IL6—chronic obstructive pulmonary disease	4.27e-06	4.59e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—CYP1A1—chronic obstructive pulmonary disease	4.24e-06	4.56e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—IL6—chronic obstructive pulmonary disease	4.23e-06	4.55e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—GSTT1—chronic obstructive pulmonary disease	4.22e-06	4.54e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—GCLC—chronic obstructive pulmonary disease	4.17e-06	4.49e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	4.15e-06	4.46e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—CYP1A1—chronic obstructive pulmonary disease	4.14e-06	4.45e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—IL6—chronic obstructive pulmonary disease	4.12e-06	4.44e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—TP53—chronic obstructive pulmonary disease	4.12e-06	4.43e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—GSTM1—chronic obstructive pulmonary disease	4.11e-06	4.42e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—GSTM1—chronic obstructive pulmonary disease	4.08e-06	4.38e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	4.07e-06	4.38e-05	CbGpPWpGaD
Imatinib—LCK—Disease—TGFB1—chronic obstructive pulmonary disease	4.05e-06	4.36e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—IL6—chronic obstructive pulmonary disease	4.02e-06	4.32e-05	CbGpPWpGaD
Imatinib—LCK—Disease—EGFR—chronic obstructive pulmonary disease	3.98e-06	4.28e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	3.93e-06	4.22e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—CYP1A1—chronic obstructive pulmonary disease	3.9e-06	4.19e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—CYP1A1—chronic obstructive pulmonary disease	3.86e-06	4.16e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	3.86e-06	4.15e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	3.85e-06	4.14e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	3.81e-06	4.1e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—IL6—chronic obstructive pulmonary disease	3.81e-06	4.09e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—CTGF—chronic obstructive pulmonary disease	3.81e-06	4.09e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—GSTP1—chronic obstructive pulmonary disease	3.79e-06	4.08e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—HMOX1—chronic obstructive pulmonary disease	3.74e-06	4.02e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—ALB—chronic obstructive pulmonary disease	3.73e-06	4.01e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—NOS3—chronic obstructive pulmonary disease	3.56e-06	3.83e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	3.54e-06	3.81e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—CYP1A2—chronic obstructive pulmonary disease	3.51e-06	3.77e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—GSTM1—chronic obstructive pulmonary disease	3.48e-06	3.75e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	3.47e-06	3.73e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	3.45e-06	3.71e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—TP53—chronic obstructive pulmonary disease	3.42e-06	3.67e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—IL6—chronic obstructive pulmonary disease	3.31e-06	3.56e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—CYP1A1—chronic obstructive pulmonary disease	3.3e-06	3.55e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—TP53—chronic obstructive pulmonary disease	3.23e-06	3.48e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—IL6—chronic obstructive pulmonary disease	3.13e-06	3.36e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	3.09e-06	3.33e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—NOS3—chronic obstructive pulmonary disease	3.07e-06	3.3e-05	CbGpPWpGaD
Imatinib—LCK—Disease—IL6—chronic obstructive pulmonary disease	3.06e-06	3.29e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—IL6—chronic obstructive pulmonary disease	2.96e-06	3.18e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—GSTP1—chronic obstructive pulmonary disease	2.93e-06	3.15e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—TP53—chronic obstructive pulmonary disease	2.91e-06	3.13e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—HMOX1—chronic obstructive pulmonary disease	2.89e-06	3.1e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—ALB—chronic obstructive pulmonary disease	2.88e-06	3.1e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	2.84e-06	3.05e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—ALB—chronic obstructive pulmonary disease	2.81e-06	3.02e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	2.78e-06	2.99e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—NOS3—chronic obstructive pulmonary disease	2.76e-06	2.96e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—NOS3—chronic obstructive pulmonary disease	2.69e-06	2.89e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—GSTM1—chronic obstructive pulmonary disease	2.69e-06	2.89e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—IL6—chronic obstructive pulmonary disease	2.67e-06	2.87e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—ALB—chronic obstructive pulmonary disease	2.65e-06	2.85e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—ALB—chronic obstructive pulmonary disease	2.63e-06	2.83e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—CYP1A1—chronic obstructive pulmonary disease	2.55e-06	2.74e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—NOS3—chronic obstructive pulmonary disease	2.53e-06	2.73e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—NOS3—chronic obstructive pulmonary disease	2.51e-06	2.7e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—TP53—chronic obstructive pulmonary disease	2.34e-06	2.51e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—ALB—chronic obstructive pulmonary disease	2.24e-06	2.41e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—NOS3—chronic obstructive pulmonary disease	2.15e-06	2.31e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—IL6—chronic obstructive pulmonary disease	2.14e-06	2.3e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—ALB—chronic obstructive pulmonary disease	1.73e-06	1.86e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—NOS3—chronic obstructive pulmonary disease	1.66e-06	1.78e-05	CbGpPWpGaD
